Veronica Sendersky

UCB Pharma (Belgium) — Belgium

Medicine · Health Sciences

6h-index679citations23works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epilepsy research and treatment(6), Pharmacological Effects and Toxicity Studies(5), Pain Management and Opioid Use(4), Neuroscience and Neuropharmacology Research(3), Health Systems, Economic Evaluations, Quality of Life(3)

Publications23 total

12-month Effectiveness and Tolerability of Brivaracetam in Patients with Epilepsy and Cognitive or Psychiatric Comorbidities: Subgroup Data from the International EXPERIENCE Pooled Analysis (P8-1.009)
Neurology·2024
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records
CNS Drugs·2023· 21 citedOpen Access
2576 12-Month effectiveness and tolerability of brivaracetam in patients with epilepsy switching from levetiracetam Vs Other antiseizure medications in the real-world
2023Open Access
2628 12-Month effectiveness and tolerability of brivaracetam in the real-world in the international EXPERIENCE pooled analysis: final results and Australian subgroup
2023Open Access
12-Month Effectiveness and Tolerability of Brivaracetam in the Real-World: The International EXPERIENCE Pooled Analysis (P11-1.003)
Neurology·2023
12-month effectiveness and tolerability of brivaracetam in the real-world: interim analysis of the international, non-interventional EXPERIENCE study (P13-8.002)
Neurology·2022
An Economic Evaluation of Short-Acting Opioids for Treatment of Breakthrough Pain in Patients with Cancer
Value in Health·2011· 30 cited
PCN101 COST-EFFECTIVENESS OF SHORT-ACTING OPIOIDS FOR BREAKTHROUGH PAIN IN CANCER PATIENTS—A SCOTTISH-BASED DECISION-ANALYSIS MODEL
Value in Health·2009
843 AN ECONOMIC EVALUATION OF FAST‐ACTING OPIOIDS FOR THE TREATMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS IN SWEDEN
European Journal of Pain·2009· 2 cited
691 THE EFFICACY OF FORMULATIONS OF ORAL MORPHINE IN THE TREATMENT OF BREAKTHROUGH PAIN (BTP) IN CANCER PATIENTS
European Journal of Pain·2009
The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer
Journal of Clinical Oncology·2008
PUK23 EVALUATION OF FACE AND CONTENT VALIDITY OF NOCTURIA QUALITY OF LIFE QUESTIONNAIRE (N-QOL)
Value in Health·2008
THE INFLUENCE OF MEDICARE REFORM ON THE UTILIZATION OF ANTI-ANDROGENS IN A COHORT OF PATIENTS WITH OF PROSTATE CANCER IN THE UNITED STATES
The Journal of Urology·2008· 2 cited
PCN73 LINGUISTIC VALIDATION OF THE HOT FLASH DIARY FOR PROSTATE CANCER PATIENTS IN EIGHT LANGUAGES FOR NINE COUNTRIES
Value in Health·2007Open Access
PIH17 ASSESSING PSYCHOLOGICAL BURDEN AND TREATMENT BENEFITS IN PEDIATRIC PATIENTS WITH BEDWETTING
Value in Health·2006
Health Status and functional limitations in chronic obstructive pulmonary disease and other chronic illnesses in a sample of US adults
CHEST Journal·2004Open Access
Inappropriate Prescribing for Elderly Americans in a Large Outpatient Population
Archives of Internal Medicine·2004· 213 cited
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients
ACC Current Journal Review·2003· 149 cited
PCHI I: ESTIMATING THE BUDGET AND HEALTH IMPACTS OF LETROZOLE FOR ADVANCED BREAST CANCER
Value in Health·2003· 4 citedOpen Access
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients
The American Journal of Medicine·2003· 174 cited
page 1 of 2Next →

Frequent Co-authors

Vicente Villanueva(6), Cédric Laloyaux(6), Wendyl D’Souza(6), Edward Faught(6), Pavel Klein(6), Markus Reuber(6), Felix Rosenow(6), Javier Salas‐Puig(6), Adam Strzelczyk(6), Jerzy P. Szaflarski(6), Tony Daniels(6), Florin Floricel(6), Bernhard J. Steinhoff(6), Víctor Soto Insuga(5), Hervé Besson(5), Debby Vissers(4), David Friesen(4), Lesley H. Curtis(3), Truls Østbye(3), Kevin A. Schulman(3)